Adult Lymphocyte Predominant Hodgkin Lymphoma

8 clinical trials · Condition

Record	Firm	Date
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (NCT02168140)	Wake Forest University Health Sciences	2014-09-01
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma (NCT01535924)	Beth Christian	2012-02-09
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma (NCT01476410)	Northwestern University	2011-11-01
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma (NCT01460940)	Ohio State University Comprehensive Cancer Center	2011-10-13
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy (NCT00381940)	National Cancer Institute (NCI)	2007-01-01
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT00337194)	National Cancer Institute (NCI)	2006-04-01
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (NCT00112723)	National Cancer Institute (NCI)	2005-12-01
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (NCT00132028)	National Cancer Institute (NCI)	2005-09-01

Every clearance here is in the API, with alerts when new ones post.